<result><Target><Item><Target_ID> 1651</Target_ID>
<Target_Name>IgG from patients with CHB with HBsAg seroclearance following peg-IFN-α therapy</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1652</Target_ID>
<Target_Name>Embryonic progenitor cell line SM30</Target_Name>
<Target_Type>Cell</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1653</Target_ID>
<Target_Name>Ovarian cancer cell lines OC-3</Target_Name>
<Target_Type>Cell</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments>The OC-3 cell line was a primary culture derived from a human surgical sample of clear cell adenocarcinoma of the ovary.</Comments>
</Item><Item><Target_ID> 1654</Target_ID>
<Target_Name>Polyclonal rabbit anti-AK IgG</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1655</Target_ID>
<Target_Name>Cyclin-dependent kinase inhibitor 2A, isoforms 1/2/3</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence>P42771</Target_Sequence>
<Synonyms>CDK4I, MTS-1, p16-INK4, p16INK4A</Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure>1A5E, 1BI7, 1DC2, 2A5E</Target_Structure>
<Comments>The target protein (p16) is a cyclin-dependent kinase (CDK) inhibitor, which plays an important role in retinoblastoma (Rb) pathway. Protein p16 has been widely used as a biomarker for HPV-related cancer diagnosis.</Comments>
</Item><Item><Target_ID> 1656</Target_ID>
<Target_Name>Soft tissue of prostate cancer xenograft</Target_Name>
<Target_Type>Organ and tissue</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments>The specimen was obtained by needle biopsy from the sacroiliac zone of an exophytic osteoblastic lesion in the left hemipelvis of a 49-y-old Caucasian male with androgen-independent prostate cancer.</Comments>
</Item><Item><Target_ID> 1657</Target_ID>
<Target_Name>Bonelike matrix tissues of prostate cancer xenograft</Target_Name>
<Target_Type>Organ and tissue</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments>The specimen was obtained by needle biopsy from the sacroiliac zone of an exophytic osteoblastic lesion in the left hemipelvis of a 49-y-old Caucasian male with androgen-independent prostate cancer.</Comments>
</Item><Item><Target_ID> 1658</Target_ID>
<Target_Name>The ligated left carotid artery in male C57/BL6J mice</Target_Name>
<Target_Type>Organ and tissue</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments>In vivo phage panning was performed in the partial carotid artery ligation model of disturbed flow in male C57/BL6J mice. In this surgical model, three of the four major branches of the left common carotid artery (LCA) are ligated. This results in low and oscillatory flow in the LCA, while flow in the right common carotid artery (RCA) remains normal. The ligated left carotid artery is the target for phage display, while the right artery serves as a normal flow control.</Comments>
</Item><Item><Target_ID> 1659</Target_ID>
<Target_Name>Polyclonal anti-LiAg IgGs</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Canis familiaris (dog):9615</Target_Source>
<Target_Structure></Target_Structure>
<Comments>Antibodies used for biopanning were purified from 38 sera from L. infantum naturally infected dogs.</Comments>
</Item><Item><Target_ID> 1660</Target_ID>
<Target_Name>Anti-human cardiac troponin I mAb 11E12</Target_Name>
<Target_Type>Protein&gt;Monoclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1661</Target_ID>
<Target_Name>Anti-HIV-1 monoclonal antibody VRC01</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1662</Target_ID>
<Target_Name>Plasma kallikrein (EC:3.4.21.34)</Target_Name>
<Target_Type>Protein&gt;Enzyme</Target_Type>
<Target_Sequence>P03952</Target_Sequence>
<Synonyms>Fletcher factor, Plasma prekallikrein, Kininogenin</Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure>2ANW, 2ANY, 4OGX, 4OGY, 5F8T, 5F8X, 5F8Z, 5TJX</Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1663</Target_ID>
<Target_Name>Human alpha-FXIIa</Target_Name>
<Target_Type>Protein&gt;Enzyme</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments>FXII is expressed as a zymogen and activated by proteolytic cleavage in a two-step process. A first cleavage gives rise to the α-FXIIa being composed of a heavy and a catalytic light chain held together by a disulfide bond. Further cleavage yields the smaller β-FXIIa, which comprises only the catalytic domain.</Comments>
</Item><Item><Target_ID> 1664</Target_ID>
<Target_Name>Human beta-FXIIa</Target_Name>
<Target_Type>Protein&gt;Enzyme</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure></Target_Structure>
<Comments>FXII is expressed as a zymogen and activated by proteolytic cleavage in a two-step process. A first cleavage gives rise to the α-FXIIa being composed of a heavy and a catalytic light chain held together by a disulfide bond. Further cleavage yields the smaller β-FXIIa, which comprises only the catalytic domain.</Comments>
</Item><Item><Target_ID> 1665</Target_ID>
<Target_Name>MgF2 nanoparticles (NPs)</Target_Name>
<Target_Type>Inorganic molecules or materials</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source></Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1973</Target_ID>
<Target_Name>EAE-brain capillary endothelial cell</Target_Name>
<Target_Type>Cell</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Rattus norvegicus (Rat):10116</Target_Source>
<Target_Structure></Target_Structure>
<Comments>Brain endothelial cells derived from four deeply anesthetized rats with acute experimental autoimmune encephalomyelitis (EAE) and four healthy rats were isolated. </Comments>
</Item><Item><Target_ID> 1666</Target_ID>
<Target_Name>Cathepsin G (EC:3.4.21.20)</Target_Name>
<Target_Type>Protein&gt;Enzyme</Target_Type>
<Target_Sequence>P08311</Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure>1AU8, 1CGH, 1KYN, 1T32</Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1667</Target_ID>
<Target_Name>Urokinase-type plasminogen activator (EC:3.4.21.73)</Target_Name>
<Target_Type>Protein&gt;Enzyme</Target_Type>
<Target_Sequence>P00749</Target_Sequence>
<Synonyms>U-plasminogen activator, uPA</Synonyms>
<Target_Source>U-plasminogen activator, uPA</Target_Source>
<Target_Structure>1C5W, 1C5X, 1C5Y, 1C5Z, 1EJN, 1F5K, 1F5L, 1F92, 1FV9, 1GI7, 1GI8, 1GI9, 1GJ7, 1GJ8, 1GJ9, 1GJA, 1GJB, 1GJC, 1GJD, 1KDU, 1LMW, 1O3P, 1O5A, 1O5B, 1O5C, 1OWD, 1OWE, 1OWH, 1OWI, 1OWJ, 1OWK, 1SC8, 1SQA, 1SQO, 1SQT, 1U6Q, 1URK, 1VJ9, 1VJA, 1W0Z, 1W10, 1W11, 1W12, 1W13, 1W14, 2FD6, 2I9A, 2I9B, 2NWN, 2O8T, 2O8U, 2O8W, 2R2W, 2VIN, 2VIO, 2VIP, 2VIQ, 2VIV, 2VIW, 2VNT, 3BT1, 3BT2, 3IG6, 3KGP, 3KHV, 3KID, 3M61, 3MHW, 3MWI, 3OX7, 3OY5, 3OY6, 3PB1, 3QN7, 3U73, 4DVA, 4DW2, 4FU7, 4FU8, 4FU9, 4FUB, 4FUC, 4FUD, 4FUE, 4FUF, 4FUG, 4FUH, 4FUI, 4FUJ, 4GLY, 4H42, 4JK5, 4JK6, 4JNI, 4JNL, 4K24, 4MNV, 4MNW, 4MNX, 4MNY, 4OS1, 4OS2, 4OS4, 4OS5, 4OS6, 4OS7</Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1668</Target_ID>
<Target_Name>Visfatin</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Unknown</Target_Source>
<Target_Structure></Target_Structure>
<Comments>Recombinant visfatin with high purity was obtained from a prokaryotic expression system.</Comments>
</Item><Item><Target_ID> 1669</Target_ID>
<Target_Name>Polyclonal anti-LiPA IgG</Target_Name>
<Target_Type>Protein&gt;Polyclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Canis familiaris (dog):9615</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1670</Target_ID>
<Target_Name>Mycobacterium tuberculosis (H37Rv)</Target_Name>
<Target_Type>Miscellaneous</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms>Mycobacterium tuberculosis strain H37Rv</Synonyms>
<Target_Source>Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv):83332</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1671</Target_ID>
<Target_Name>B3β2γ</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Unkown</Target_Source>
<Target_Structure></Target_Structure>
<Comments>B3β2γ, with the sequence of LSALEKELASLEKE, is based on Acid-pp. The molecule possesses a pentad of alternating βand γ-amino acids, showed as βLγDβLγKβK.</Comments>
</Item><Item><Target_ID> 1672</Target_ID>
<Target_Name>B3β2γ-variant1</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Unkown</Target_Source>
<Target_Structure></Target_Structure>
<Comments>B3β2γ-variant1, with the sequence of LSALEKELASLEKE, is based on Acid-pp. The molecule possesses a pentad of alternating βand γ-amino acids, showned as βAγDβAγKβK.</Comments>
</Item><Item><Target_ID> 1673</Target_ID>
<Target_Name>Anti-NTX monoclonal antibody BNTX21</Target_Name>
<Target_Type>Protein&gt;Monoclonal antibody</Target_Type>
<Target_Sequence></Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Mus musculus (Mouse):10090</Target_Source>
<Target_Structure></Target_Structure>
<Comments></Comments>
</Item><Item><Target_ID> 1674</Target_ID>
<Target_Name>Fibroblast growth factor 23(180-205)</Target_Name>
<Target_Type>Protein&gt;Others</Target_Type>
<Target_Sequence>Q9GZV9 [180-205]</Target_Sequence>
<Synonyms></Synonyms>
<Target_Source>Homo sapiens (Human):9606</Target_Source>
<Target_Structure>2P39</Target_Structure>
<Comments>Fibroblast growth factor 23 (FGF23) is a bone-derived endocrine regulator of phosphate homeostasis and has been considered as a potential therapeutic target for hypophosphatemic disorders.</Comments>
</Item></Target></result>